Buy a-pihp Powder αlpha-Pyrrolidinohexanophenone Safely

What is A-PiHP Powder

α-PHiP (also known as α-PiHP), is a stimulant drug of the cathinone class that has been sold online as a designer drug.

It is a positional isomer of pyrovalerone, with the methyl group shifted from the 4-position of the aromatic ring to the 4-position of the acyl chain.

In a classic 2006 study of pyrrolidinyl cathinone derivatives by Meltzer et al. at Organix, the alpha-isobutyl derivative of pyrovalerone, O-2494,

was found to have the highest potency in vitro as an inhibitor of the dopamine transporter of the alpha substituted derivatives tested,

However it was not until ten years later in July 2016 that α-PHiP was first identified as a designer drug, when it was reported to the EMCDDA by a forensic laboratory in Slovenia.

How can I get A-PiHP crystal

α-Pyrrolidinoisohexanophenone (mainly known as A-PiHP or α-PiHP) is a stimulant drug of the cathinone class that has been sold online as a designer drug.

It acts as a potent norepinephrine-dopamine reuptake inhibitor (NDRI). In July 2016 α-PiHP was first identified as a designer drug when it was reported to the EMCDDA by a forensic laboratory in Slovenia.

It is a positional isomer of pyrovalerone, with the methyl group shifted from the 4-position of the aromatic ring to the 4-position of the acyl chain.

Similarly to other cathinones, use of α-PiHP can result in compulsive redosing, addiction, anxiety, paranoia, and psychosis.

Pharmacology

In a classic 2006 study of pyrrolidinyl cathinone derivatives by Meltzer et al. at Organix, the alpha-isobutyl derivative of pyrovalerone, O-2494,

was found to have the highest potency in vitro as an inhibitor of the dopamine transporter of the alpha substituted derivatives tested.

Compared to α-PVP and α-PHP, α-PiHP displays a higher selectivity for the dopamine transporter.

Where can I get A-PiHP

α-Pyrrolidinoisohexanophenone (mainly known as A-PiHP or α-PiHP) is a stimulant drug of the cathinone class that has been sold online as a designer drug.

It acts as a potent norepinephrine-dopamine reuptake inhibitor (NDRI). In July 2016 α-PiHP was first identified as a designer drug when it was reported to the EMCDDA by a forensic laboratory in Slovenia.